Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.
Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.
A humorous discussion about hair loss treatments, specifically mentioning the use of 5mg of Dutasteride. The conversation includes jokes about the effectiveness of the treatment.
Clascoterone (CB) shows an excellent safety profile with no serious side effects, but its effectiveness may decline after six months, making it more suitable as an adjunct treatment with finasteride and minoxidil rather than a standalone solution. Some argue it could be better than finasteride due to its protection against testosterone, but its long-term efficacy remains debated.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.
RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.
A user seeks advice on mixing RU58841 serum using European ingredients, specifically struggling to find propylene glycol. They are looking for alternatives to American products commonly recommended in guides.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.
A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
The conversation is about using oral finasteride and minoxidil for hair loss, with consideration of adding topical GHK-Cu for skin and hair benefits. The user seeks opinions on this combination.
A user started taking finasteride 1mg/day for hair loss but hasn't seen results yet. They also take vitamins and asked about adding minoxidil and the effectiveness of LLLT.
KX-826 stopped hair loss for the user after stopping finasteride due to mild side effects. The user experienced mild headaches initially with KX-826, which resolved after a few days.
The conversation is about a user offering an unopened bottle of KX-826 (0.5%) for hair loss treatment, stating it works well for them. They are selling it at cost without seeking profit.
The conversation discusses the use of RU58841 for hair loss, focusing on its side effects, standardization issues, and user experiences. The user also inquires about the use of other treatments like minoxidil, finasteride, and microneedling.
GHK-Cu is being discussed as a potential treatment for male pattern baldness. Users are sharing experiences and asking about its effectiveness and side effects.
User shares a topical hair loss solution using melatonin and cetirizine to help reduce shedding and itching. Instructions provided for creating and using the mixture, with additional lifestyle tips for overall hair health.